Continued process verification: Difference between revisions

Revision as of 06:44, 22 May 2019

Revision as of 09:02, 16 August 2019

Line 1:

'''Continued process verification''' ('''CPV''') is the collection and analysis of end-to-end production components and processes data to ensure product outputs are within predetermined quality limits. In 2011 the [[Food and Drug Administration]] published a report<ref>{{cite web |title= Process Validation: General Principles and Practices |url=http://www.fda.gov/downloads/Drugs/Guidances/UCM070336.pdf |publisher=FDA |accessdate= 3 November 2014}}</ref> outlining best practices regarding business process validation in the [[pharmaceutical industry]]. Continued process verification is outlined in this report as the third stage in [[process validation]]. Its central purpose is to ensure that processes are in a constant state of control, thus ensuring final product quality. Central to effective CPV is a method with which to identify unwanted process inconsistencies in order to execute corrective or preventativepreventive measures. Once quality standards are set in place they must be monitored with regular frequency to confirm those parameters are being met. Continued process verification not only helps protect consumers from production faults, but business also see benefits in implementing a CPV program. Should product outputs not match target standards it can be very costly to investigate the problem source without existing CPV data.

==Vital components of continued process verification==